In late 2020, the US Food and Drug Administration (FDA) approved plasma kallikrein inhibitor berotralstat, making it the first oral, once-a-day treatment available for the
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
